What is FluoSphera?
FluoSphera is at the forefront of next-generation drug discovery, leveraging a proprietary technology platform that employs human multi-tissue systems for precise prediction of clinical drug responses. Their suite of offerings, including FluoSelect for selective therapy discovery, FluoScore for optimal drug selection, and FluoXplore for systemic biomarker identification, is designed to revolutionize the pharmaceutical research and development pipeline. By providing high-resolution drug profiling and in vitro human physiological evaluations, FluoSphera empowers pharmaceutical companies and researchers with more reliable and relevant solutions for identifying effective treatments.
How much funding has FluoSphera raised?
FluoSphera has raised a total of $1.4M across 1 funding round:
Other Financing Round
$1.4M
Other Financing Round (2026): $1.4M with participation from Soulmates Ventures and IndieFund.It
Key Investors in FluoSphera
Soulmates Ventures
Soulmates Ventures is a sustainable venture capital fund that accelerates innovative entrepreneurs focused on creating profitable and sustainable solutions for the future. The fund invests up to 3 million in early-stage companies that aim to positively impact areas such as air, water, energy, mobility, education, healthcare, food and agriculture, and the circular economy.
IndieFund.It
IndieBio, established by SOSV in 2015, is a pioneering biotech program located in San Francisco that provides bio-labs and pre-seed investment to scientists aiming to launch startups. The program has successfully graduated 310 startups and raised $3.6 billion, focusing on sectors such as food, agriculture, industrial decarbonization, AI, therapeutics, and diagnostics.
What's next for FluoSphera?
With the recent infusion of major strategic capital, FluoSphera is poised for accelerated growth and market penetration. The company's focus on enhancing the drug discovery pipeline through advanced in vitro human physiological evaluations suggests a strategic expansion into broader therapeutic areas and deeper collaborations with leading pharmaceutical entities. This substantial backing is expected to fuel further technological development, expand its research capabilities, and solidify its position as a key innovator in the competitive landscape of drug discovery and development.
See full FluoSphera company page
